Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956252 | 0.93 | LIPG (0.60) | LIPGLIPECYP3A4HRH3HSD11B1 | |
| SCHEMBL7956524 | 0.93 | LIPG (0.60) | LIPGLIPECYP3A4HRH3HSD11B1 | |
| SCHEMBL7961497 | 0.93 | LIPG (0.60) | LIPGLIPECYP3A4HRH3HSD11B1 | |
| SCHEMBL13279901 | 0.86 | LIPG (0.55) | LIPGLIPECYP3A4HRH3EPHX2 | |
| SCHEMBL7956670 | 0.85 | LIPG (0.52) | LIPGLIPEHRH3 | |
| SCHEMBL7954969 | 0.82 | LIPG (0.53) | LIPGLIPEHRH3 | |
| SCHEMBL7958355 | 0.81 | HRH3 (0.42) | HRH3 | |
| SCHEMBL7956692 | 0.81 | FPR2 (0.47) | HRH3GPR119 | |
| SCHEMBL7956483 | 0.81 | HRH3 (0.44) | HRH3GPR119 | |
| SCHEMBL20070180 | 0.80 | LIPE (0.57) | LIPGLIPEEPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |